Patents by Inventor Xiao Guan Radstrom
Xiao Guan Radstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11971409Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.Type: GrantFiled: June 4, 2020Date of Patent: April 30, 2024Assignee: Bruker Cellular Analysis, Inc.Inventors: Kevin T. Chapman, Mark P. White, Xiaohua Wang, Minha Park, Guido K. Stadler, Randall D. Lowe, Jr., Xiao Guan Radstrom, Jason M. McEwen, Gang F. Wang, George L. Fox, Peggy A. Radel
-
Publication number: 20230100306Abstract: Bioreactors configured to scale-up the production of greater quantities of cells at relatively low cost are provided. These bioreactors may be utilized in the production of large-scale quantities of cell-based meat and cell-based fat. The bioreactors may be reusable and may have a high surface area-to-volume ratio for adherent cell expansion. The bioreactors may be capable of yielding a large number of adherent cells per bioreactor unit.Type: ApplicationFiled: September 1, 2022Publication date: March 30, 2023Inventors: George C. ENGELMAYR, Jr., Ilan Eitan FISCHER, Andre BERGERON, Saam SHAHROKHI, William C. PATON, Viktor MACIAG, Xiao Guan RADSTROM, Amelia BEVILLE, Robert YAMAN
-
Patent number: 11273177Abstract: The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.Type: GrantFiled: April 14, 2017Date of Patent: March 15, 2022Assignee: Berkeley Lights, Inc.Inventors: Kevin T Chapman, Xiaohua Wang, Xiao Guan Radstrom, Yelena Bronevetsky, Guido K Stadler, Gregory G Lavieu, Annamaria Mocciaro
-
Patent number: 11103870Abstract: Methods are described herein for isolating clonal populations of cells having a defined genetic modification. The methods are performed, at least in part, in a microfluidic device comprising one or more sequestration pens. The methods include the steps of: maintaining individual cells (or precursors thereof) that have undergone a genomic editing process in corresponding sequestration pens of a microfluidic device; expanding the individual cells into respective clonal populations of cells; and detecting, in one or more cells of each clonal population, the presence of a first nucleic acid sequence that is indicative of the presence of an on-target genome edit in the clonal population of cells. Also described are methods of performing genome editing within a microfluidic device, and compositions comprising one or more clonal populations of cells generated according to the methods disclosed herein.Type: GrantFiled: January 28, 2019Date of Patent: August 31, 2021Assignee: Berkeley Lights, Inc.Inventors: Gregory G. Lavieu, Annamaria Mocciaro, Xiao Guan Radstrom, Jason M. McEwen, Magali Soumillon, J. Tanner Nevill, Volker L. S. Kurz, Patricia A. Dyck, Ravi K. Ramenani
-
Publication number: 20200400669Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.Type: ApplicationFiled: June 4, 2020Publication date: December 24, 2020Applicant: Berkeley Lights, Inc.Inventors: Kevin T. Chapman, Mark P. White, Xiaohua Wang, Minha Park, Guido K. Stadler, Randall D. Lowe, JR., Xiao Guan Radstrom, Jason M. McEwen, Gang F. Wang, George L. Fox, Peggy A. Radel
-
Patent number: 10712344Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.Type: GrantFiled: January 13, 2017Date of Patent: July 14, 2020Assignee: Berkeley Lights, Inc.Inventors: Kevin T. Chapman, George L. Fox, Peggy A. Radel, Mark P. White, Xiaohua Wang, Minha Park, Guido K. Stadler, Randall D. Lowe, Jr., Xiao Guan Radstrom, Jason M. McEwen, Gang F. Wang
-
Publication number: 20190217297Abstract: Methods are described herein for isolating clonal populations of cells having a defined genetic modification. The methods are performed, at least in part, in a microfluidic device comprising one or more sequestration pens. The methods include the steps of: maintaining individual cells (or precursors thereof) that have undergone a genomic editing process in corresponding sequestration pens of a microfluidic device; expanding the individual cells into respective clonal populations of cells; and detecting, in one or more cells of each clonal population, the presence of a first nucleic acid sequence that is indicative of the presence of an on-target genome edit in the clonal population of cells. Also described are methods of performing genome editing within a microfluidic device, and compositions comprising one or more clonal populations of cells generated according to the methods disclosed herein.Type: ApplicationFiled: January 28, 2019Publication date: July 18, 2019Applicant: Berkeley Lights, Inc.Inventors: Gregory G. Lavieu, Annamaria Mocciaro, Xiao Guan Radstrom, Jason M. McEwen, Magali Soumillon, J. Tanner Nevill, Volker L.S. Kurz, Patricia A. Dyck, Ravi K. Ramenani
-
Patent number: 10239058Abstract: Methods are described herein for isolating clonal populations of cells having a defined genetic modification. The methods are performed, at least in part, in a microfluidic device comprising one or more sequestration pens. The methods include the steps of: maintaining individual cells (or precursors thereof) that have undergone a genomic editing process in corresponding sequestration pens of a microfluidic device; expanding the individual cells into respective clonal populations of cells; and detecting, in one or more cells of each clonal population, the presence of a first nucleic acid sequence that is indicative of the presence of an on-target genome edit in the clonal population of cells. Also described are methods of performing genome editing within a microfluidic device, and compositions comprising one or more clonal populations of cells generated according to the methods disclosed herein.Type: GrantFiled: November 2, 2017Date of Patent: March 26, 2019Assignee: Berkeley Lights, Inc.Inventors: Gregory G. Lavieu, Annamaria Mocciaro, Xiao Guan Radstrom, Jason M. McEwen, Magali Soumillon, J. Tanner Nevill, Volker L. S. Kurz, Patricia A. Dyck, Ravi K. Ramenani
-
Publication number: 20180147576Abstract: Methods are described herein for isolating clonal populations of cells having a defined genetic modification. The methods are performed, at least in part, in a microfluidic device comprising one or more sequestration pens. The methods include the steps of: maintaining individual cells (or precursors thereof) that have undergone a genomic editing process in corresponding sequestration pens of a microfluidic device; expanding the individual cells into respective clonal populations of cells; and detecting, in one or more cells of each clonal population, the presence of a first nucleic acid sequence that is indicative of the presence of an on-target genome edit in the clonal population of cells. Also described are methods of performing genome editing within a microfluidic device, and compositions comprising one or more clonal populations of cells generated according to the methods disclosed herein.Type: ApplicationFiled: November 2, 2017Publication date: May 31, 2018Inventors: Gregory G. Lavieu, Annamaria Mocciaro, Xiao Guan Radstrom, Jason M. McEwen, Magali Soumillon, J. Tanner Nevill, Volker L.S. Kurz, Patricia A. Dyck, Ravi K. Ramenani
-
Publication number: 20170224734Abstract: The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.Type: ApplicationFiled: April 14, 2017Publication date: August 10, 2017Inventors: Kevin T Chapman, Xiaohua Wang, Xiao Guan Radstrom, Yelena Bronevetsky, Guido K Stadler, Gregory G Levieu, Annamaria Mocciaro